AtriCure, Inc. (ATRC)
USD 30.61
(-3.1%)
USD 30.61
(-3.1%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 60.59 Million USD | -12.28% |
| 2022 | 69.07 Million USD | -6.52% |
| 2021 | 73.89 Million USD | 12.67% |
| 2020 | 65.58 Million USD | -11.62% |
| 2019 | 74.2 Million USD | 55.42% |
| 2018 | 47.74 Million USD | 29.52% |
| 2017 | 36.86 Million USD | -0.92% |
| 2016 | 37.2 Million USD | 171.37% |
| 2015 | 13.71 Million USD | 18427.03% |
| 2014 | 74 Thousand USD | -98.32% |
| 2013 | 4.41 Million USD | -31.14% |
| 2012 | 6.4 Million USD | 30.07% |
| 2011 | 4.92 Million USD | 644.5% |
| 2010 | 661.62 Thousand USD | -75.22% |
| 2009 | 2.66 Million USD | -55.78% |
| 2008 | 6.03 Million USD | 2037.04% |
| 2007 | 282.47 Thousand USD | -59.21% |
| 2006 | 692.54 Thousand USD | -36.11% |
| 2005 | 1.08 Million USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 61.86 Million USD | 0.0% |
| 2024 Q1 | 61.86 Million USD | 2.1% |
| 2024 Q3 | 61.86 Million USD | 0.0% |
| 2023 Q3 | 53.67 Million USD | -9.21% |
| 2023 Q4 | 60.59 Million USD | 12.89% |
| 2023 FY | 60.59 Million USD | -12.28% |
| 2023 Q1 | 64.54 Million USD | -6.56% |
| 2023 Q2 | 59.11 Million USD | -8.41% |
| 2022 Q4 | 69.07 Million USD | -5.09% |
| 2022 Q1 | 73.55 Million USD | -0.45% |
| 2022 Q3 | 72.78 Million USD | -0.5% |
| 2022 FY | 69.07 Million USD | -6.52% |
| 2022 Q2 | 73.14 Million USD | -0.56% |
| 2021 FY | 73.89 Million USD | 12.67% |
| 2021 Q1 | 60.26 Million USD | -8.11% |
| 2021 Q2 | 56.04 Million USD | -7.01% |
| 2021 Q3 | 68.26 Million USD | 21.81% |
| 2021 Q4 | 73.89 Million USD | 8.24% |
| 2020 Q2 | 67.11 Million USD | -7.34% |
| 2020 FY | 65.58 Million USD | -11.62% |
| 2020 Q1 | 72.42 Million USD | -2.4% |
| 2020 Q4 | 65.58 Million USD | 4.97% |
| 2020 Q3 | 62.48 Million USD | -6.9% |
| 2019 Q2 | 46.87 Million USD | 1.72% |
| 2019 FY | 74.2 Million USD | 55.42% |
| 2019 Q1 | 46.07 Million USD | -3.49% |
| 2019 Q4 | 74.2 Million USD | -0.07% |
| 2019 Q3 | 74.25 Million USD | 58.43% |
| 2018 Q3 | 50.89 Million USD | -1.93% |
| 2018 FY | 47.74 Million USD | 29.52% |
| 2018 Q4 | 47.74 Million USD | -6.18% |
| 2018 Q2 | 51.89 Million USD | -0.09% |
| 2018 Q1 | 51.93 Million USD | 40.91% |
| 2017 Q3 | 31.59 Million USD | -5.59% |
| 2017 Q4 | 36.86 Million USD | 16.65% |
| 2017 Q1 | 35.33 Million USD | -5.02% |
| 2017 FY | 36.86 Million USD | -0.92% |
| 2017 Q2 | 33.46 Million USD | -5.29% |
| 2016 Q4 | 37.2 Million USD | -3.23% |
| 2016 Q3 | 38.44 Million USD | -0.07% |
| 2016 Q2 | 38.47 Million USD | 183.06% |
| 2016 Q1 | 13.59 Million USD | -0.86% |
| 2016 FY | 37.2 Million USD | 171.37% |
| 2015 Q4 | 13.71 Million USD | 20061.76% |
| 2015 Q1 | 79 Thousand USD | 6.76% |
| 2015 Q2 | 68 Thousand USD | -13.92% |
| 2015 Q3 | 68 Thousand USD | 0.0% |
| 2015 FY | 13.71 Million USD | 18427.03% |
| 2014 Q3 | 55 Thousand USD | -15.38% |
| 2014 Q1 | 69 Thousand USD | -98.44% |
| 2014 FY | 74 Thousand USD | -98.32% |
| 2014 Q2 | 65 Thousand USD | -5.8% |
| 2014 Q4 | 74 Thousand USD | 34.55% |
| 2013 Q2 | 5.39 Million USD | -8.61% |
| 2013 Q4 | 4.41 Million USD | -10.36% |
| 2013 FY | 4.41 Million USD | -31.14% |
| 2013 Q1 | 5.89 Million USD | -7.93% |
| 2013 Q3 | 4.92 Million USD | -8.7% |
| 2012 Q4 | 6.4 Million USD | -6.69% |
| 2012 Q2 | 7.36 Million USD | -6.44% |
| 2012 Q1 | 7.87 Million USD | 59.83% |
| 2012 FY | 6.4 Million USD | 30.07% |
| 2012 Q3 | 6.86 Million USD | -6.79% |
| 2011 FY | 4.92 Million USD | 644.5% |
| 2011 Q4 | 4.92 Million USD | -6.82% |
| 2011 Q3 | 5.28 Million USD | -6.77% |
| 2011 Q2 | 5.67 Million USD | -6.34% |
| 2011 Q1 | 6.05 Million USD | 815.0% |
| 2010 Q1 | 2.17 Million USD | -18.52% |
| 2010 FY | 661.62 Thousand USD | -75.22% |
| 2010 Q4 | 661.62 Thousand USD | -43.53% |
| 2010 Q3 | 1.17 Million USD | -30.09% |
| 2010 Q2 | 1.67 Million USD | -22.95% |
| 2009 Q3 | 3.09 Million USD | -13.58% |
| 2009 FY | 2.66 Million USD | -55.78% |
| 2009 Q1 | 27.7 Thousand USD | -99.54% |
| 2009 Q2 | 3.58 Million USD | 12823.73% |
| 2009 Q4 | 2.66 Million USD | -13.72% |
| 2008 Q2 | 538.61 Thousand USD | 121.27% |
| 2008 FY | 6.03 Million USD | 2037.04% |
| 2008 Q4 | 6.03 Million USD | -0.14% |
| 2008 Q3 | 6.04 Million USD | 1022.39% |
| 2008 Q1 | 243.41 Thousand USD | -13.83% |
| 2007 Q4 | 282.47 Thousand USD | -26.55% |
| 2007 Q2 | 484.69 Thousand USD | -17.8% |
| 2007 Q1 | 589.66 Thousand USD | -14.86% |
| 2007 FY | 282.47 Thousand USD | -59.21% |
| 2007 Q3 | 384.59 Thousand USD | -20.65% |
| 2006 FY | 692.54 Thousand USD | -36.11% |
| 2006 Q1 | 989.06 Thousand USD | -8.76% |
| 2006 Q3 | 793.37 Thousand USD | -11.08% |
| 2006 Q2 | 892.2 Thousand USD | -9.79% |
| 2006 Q4 | 692.54 Thousand USD | -12.71% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | 1.08 Million USD | -12.98% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | 1.24 Million USD | 0.0% |
| 2005 FY | 1.08 Million USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 75.25 Million USD | 19.482% |
| AngioDynamics, Inc. | 3.93 Million USD | -1438.284% |
| Avinger, Inc. | - USD | -Infinity% |
| Azenta, Inc. | 60.43 Million USD | -0.26% |
| BioLife Solutions, Inc. | 18.31 Million USD | -230.91% |
| The Cooper Companies, Inc. | 2.52 Billion USD | 97.599% |
| Daxor Corporation | 755.65 Thousand USD | -7918.564% |
| Ekso Bionics Holdings, Inc. | 4.83 Million USD | -1153.994% |
| Femasys Inc. | 4.25 Million USD | -1322.979% |
| GlucoTrack, Inc. | 196 Thousand USD | -30814.796% |
| Harvard Bioscience, Inc. | 30.7 Million USD | -97.346% |
| Hologic, Inc. | 2.49 Billion USD | 97.573% |
| ICU Medical, Inc. | 1.57 Billion USD | 96.16% |
| Intuitive Surgical, Inc. | -82.1 Million USD | 173.804% |
| KORU Medical Systems, Inc. | 3.65 Million USD | -1558.754% |
| LeMaitre Vascular, Inc. | 16.62 Million USD | -264.491% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 871.7 Million USD | 93.049% |
| Microbot Medical Inc. | 40 Thousand USD | -151382.5% |
| Meihua International Medical Technologies Co., Ltd. | 4592.00 USD | -1319433.972% |
| Merit Medical Systems, Inc. | 823.01 Million USD | 92.638% |
| Nephros, Inc. | 1.39 Million USD | -4259.209% |
| NovoCure Limited | 596.24 Million USD | 89.838% |
| NEXGEL, Inc. | 513 Thousand USD | -11711.501% |
| NEXGEL, Inc. | 513 Thousand USD | -11711.501% |
| Singular Genomics Systems, Inc. | 67.52 Million USD | 10.264% |
| OraSure Technologies, Inc. | 11.38 Million USD | -432.078% |
| Pro-Dex, Inc. | 7.53 Million USD | -704.047% |
| Pulse Biosciences, Inc. | 8.08 Million USD | -649.357% |
| Predictive Oncology Inc. | 2.18 Million USD | -2668.094% |
| Precision Optics Corporation, Inc. | 1.93 Million USD | -3026.622% |
| QuidelOrtho Corporation | 2.27 Billion USD | 97.336% |
| Repligen Corporation | 510.14 Million USD | 88.122% |
| Sanara MedTech Inc. | 9.11 Million USD | -564.898% |
| STAAR Surgical Company | 31.46 Million USD | -92.56% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 295 Thousand USD | -20440.0% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 96.626% |
| Jin Medical International Ltd. | - USD | -Infinity% |